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Summary We have studied the influence of the peripheral vasodilator hydralazine (HDZ) on the vasculature
and blood perfusion of two members of a series of subcutaneous murine adenocarcinomata of the colon
(MAC tumours), and the influence of HDZ on the efficacy and/or toxicity of TCNU and melphalan. The
fluorescent DNA stain Hoechst 33342, showed that HDZ caused a shutdown of tumour vasculature, related in
magnitude to both dose and tumour differentiation state; 10 mg kg-' caused an 80% vascular shutdown of
well differentiated MAC 26 tumours, but only a 50% shutdown of the poorly differentiated MAC 15A
tumours. 2.5 mg kg-' was ineffective. The blood perfusion marker 99mTc-HMPAO showed that the normal
perfusion of MAC tumours was consistently markedly less than that of lung, liver or kidneys (4-5% of lung
perfusion). HDZ (10 mg kg-') decreased MAC 26 perfusion by 63%, and that of MAC 15A by 20%. Again,
2.5 mg kg-') was ineffective. Use of in vivo to in vitro clonogenic assays showed that HDZ (10 mgkg-')
potentiated the efficacy of melphalan ( -Omg kg-' i.p.) by a factor of 2.1, and increased the efficacy of
TCNU ( -1O mg kg-' i.v., factor = 1.7) when given 10 or 15 min respectively after dosing. However, the
addition of HDZ increased the acute bone marrow toxicity of melphalan, but not that of TCNU. The clinical
relevance of these results is discussed.
An important factor influencing the delivery and therefore
effectiveness of antitumour agents is the relative perfusion of
tumour and other tissues with blood. It has been known for
more than 40 years (Algire & Legallais, 1951) that perfusion
of experimental tumours can be manipulated by the use of
vasoactive agents, and a recent paper (Hirst & Wood, 1989)
cites more than 25 compounds with the demonstrated ability
to alter experimental tumour blood flow, the majority of
these causing a decrease.
Typical of these is the antihypertensive hydralazine (HDZ),
which has been shown to decrease the blood flow through
experimental tumours when administered at doses ranging
from 0.5-10 mg kg-' either intraperitoneally (i.p.) (Brown
1987; Babbs et al., 1982) or intravenously (i.v.) (Chan et al.,
1984; Voorhees & Babbs, 1982). The results presented for the
influence of lower doses of HDZ appear contradictory: Kal-
mus et al. (1990) showed that 0.25 mg kg-' HDZ slightly
increased the blood flow through FSall tumours when ad-
ministered i.p., whereas Brown (1987), showed that, at this
dose, HDZ caused a slight decrease in the blood flow
through SCCVII tumours. The influence of HDZ on tumour
blood flow is thought to be mainly via two mechanisms:
firstly the blood vessels within most experimental tumours
cannot be dilated because they are poorly formed, lacking
smooth muscle and innervation (Denekamp, 1986; Chaplin,
1987), and maximally dilated already (Chaplin, 1987), and
secondly, if the level of the arterial blood pressure drops
below that of the intratumoural interstitial pressure (reported
to be abnormally high (Wiig et al., 1982)), the tumour vas-
culature will collapse. Also contributing are secondary effects
such as the induction of red blood cell rigidity at low pH and
homeostatic mechanisms diverting blood flow to critical
organs and away from the extremities (Kalmus et al., 1990).
Overall, the effect of HDZ will be to cause both an absolute
and relative decrease in tumour perfusion (Chan et al., 1984;
Jirtle, 1988).
HDZ has also been shown to enhance the effectiveness of
'bioreductive' agents such as the nitroimidazole RSU 1069
(Chaplin & Acker, 1987) and the benzotriazine di-N-oxide
SR 4233 (Brown, 1987), and to increase the efficacy and
therapeutic index of the bifunctional nitrogen mustard, L-
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phenylalanine mustard (melphalan) (Stratford et al., 1988).
In the case of melphalan, it was suggested that HDZ
decreased the rate of tumour clearance, improving melphalan
efficacy by increasing the exposure of tumour cells (Stratford
et al., 1987, 1988).
The present study aimed to use both the vital bis-benza-
mide fluorescent dye Hoechst 33342 (H33342) and the blood
flow marker technetium-99m labelled hexamethylpropylene-
amine oxime (9mTc-HMPAO) to characterise the vasculature
and perfusion of two members of a panel of transplantable
adenocarcinomata of the mouse colon (MAC tumours). This
panel, which was derived from a series of primary tumours
induced in NMRI mice by prolonged administration of 1,2-
dimethylhydrazine (Double et al., 1975) has been shown to
be a good model for clinical large bowel cancer in terms of
range of histology and chemosensitivity (Double & Ball,
1975). These two agents were used to investigate the influence
of HDZ on the vasculature and perfusion of these MAC
tumours. We investigated by the use of both in vivo to in
vitro clonogenic assays and in vivo tumour growth inhibition
assays the influence of HDZ on the efficacy of both mel-
phalan and tauromustine (TCNU) against tumours. TCNU
(1-(2-chloroethyl) -3-[2-(dimethyl-amino-sulphonyl) ethyl]-1-
nitrosourea) is a novel nitrosourea shown to have good
activity both clinically (Smyth et al., 1987; Gundersen et al.,
1989) and against the MAC tumours (Bibby et al., 1988),
(also reviewed in Workman, 1987), whose dose limiting tox-
icity in patients is myelosuppression (Smyth et al., 1987;
Gundersen et al., 1989). A positive correlation has been
demonstrated between the in vivo and in vitro sensitivity of
the MAC tumours to TCNU (Phillips et al., 1988). Finally,
we investigated the influence of HDZ on the acute bone
marrow toxicity of TCNU and melphalan in mice by the use
of the spleen colony unit assay of Till & McCulloch (1961).
Materials and methods
Animals
Pure strain NMRI male mice, aged 6-8 weeks, from our
inbred colony were used. The mice received CRM Diet (Lab-
sure, Croydon, England) and water ad libitum. All animal
procedures were carried out under a project license issued by
the Home Office, London, and.UKCCCR guidelines (Work-
man et al., 1988) for the use of animals in experiments were
adhered to throughout.
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Tumour system
Two different tumours have been used in the present study:
MAC 15A - a rapidly growing, poorly differentiated tumour
induced by the subcutaneous (s.c.) injection of a suspension
of 1 x 106 ascites tumour cells, and MAC 26 - a slow grow-
ing, well differentiated cystic tumour induced by s.c. implan-
tation of solid tumour fragments. Mice bearing MAC 15A
tumours were treated after 7 days, and MAC 26 tumour
bearing animals were treated after 16 days. At the time of
treatment, the mean tumour volume of the MAC 15A tu-
mours were 624 mm3 (range = 162-1300), and that of the
MAC 26 tumours was 109 mm3 (range = 30-360). These
sizes were chosen in view of data obtained in preliminary
investigation, which showed that, whereas MAC 26 tumours
had an established vasculature from the time when they were
just palpable, MAC 15A tumours needed to be well estab-
lished before they had a consistent, measurable vasculature.
Mice were allocated to groups so that variation in group
mean tumour sizes was within 10%.
Test compounds
H33342, TCNU and HDZ were dissolved in sterile physio-
logical saline. Melphalan was dissolved in 2% acid alcohol
and then diluted 1 in 10 in propylene glycol buffer. TCNU
and HDZ (administered intravenously (i.v.) via the tail vein)
and melphalan (intraperitoneally (i.p.)) were administered in
1 ml per 100 g bodyweight, and H33342 was administered i.v.
in 0.5 ml per 100 g bodyweight. The HDZ and H33342 were
obtained from Sigma, TCNU and melphalan were gifts from
Pharmacia Leo and Burroughs Wellcome & Co. respectively.
All drugs were prepared immediately before use.
Tumour vasculature and bloodflow
H33342 The use of fluorescent dye, H33342, to visualise
and quantify tumour functional vasculature when frozen sec-
tions are viewed under ultraviolet light has been described
(Smith et al., 1988). H33342 was administered at 40 mg kg-',
and tumours removed 1 min after dosing. This dose was
chosen in view of preliminary investigations, where 40 mg
kg-' was shown to give the clearest, most consistent visual-
isation of the tumour blood vessels. It has been established
that H33342 is vasoactive at doses above 10 mg kg-' (Trotter
et al., 1990). However, this would not alter the validity of
these experiments, as only the absolute values of tumour
vasculature obtained might be altered, not their relative
values, and all results for treated tumours were compared to
those obtained for controls. Tumours were snap frozen in
liquid nitrogen, and stored at - 20°C until sectioning at
8-lOiLm using a Bright cryostat. Sections were air dried and
then examined under ultraviolet illumination using a Vickers
microscope fitted with an epifluorescent source
(magnification x 250). Adjacent sections to those used for the
vascular quantification were retained, air dried for at least
24 h and then stained using Haematoxylin and Eosin (H &
E). Vascular quantification was by use of a point scoring
system similar to that described by Chalkley (1943). Briefly, a
graticule with a grid of 400 points was focused on five
different areas of each of 10-20 sections per tumour, and a
count made of the number of points falling within the
fluorescent haloes of H33342 labelled cells. The percentage
functional vasculature was calculated for each tumour from
the equation:
% vasculature = (No. of positive points/total points) x 100
This technique was used to investigate the influence of HDZ
(2.5-10 mg kg-') on the functional vasculature of both tu-
mours and that of TCNU (30 mg kg-') on the vasculature of
MAC 26 tumours. In the case of the HDZ, H33342 was
administered 5 min after dosing, and in the case of the
TCNU, 10 min after.
99Tc-HMPAO The use of 9'Tc-HMPAO to measure clin-
ical (Holmes et al., 1985; Ell et al., 1985; Rowell et al., 1990),
and experimental (Hammersley et al., 1987) blood flow has
been described. This technique relies on the principle, first
described by Sapirstein (1956) that, for a given time after its
intravenous administration, the fractional distribution of an
indicator among the organs will correspond to the fractional
distribution of the cardiac output amongst them. Work-up
experiments using non-tumour bearing NMRI mice showed
that relative tissue levels of 99mTc-HMPAO remained con-
stant between 10 min and 1 h after administration, and that
the radiochemical purity of the `mTc-HMPAO was not
significantly reduced for at least an hour after the addition of
the 99mTc.
Non-anaesthetised mice were killed by cervical dislocation
10 min after i.v. administration of 37 kBq of 99mTc-HMPAO
(0.1 ml). Lung, liver, kidney, tumour and tail tissues were
removed. The lungs were washed by brief immersion in
isoton to remove any surface blood contamination and then
blotted. All tissues were weighed, and the radioactivity pres-
ent in each tissue/organ measured by use of a Wallac 1282
Compugamma Gamma Counter. The radioactivity/g tissue
was then calculated for each sample and results normalised
for radioactivity remaining in the tails, and for radioactive
decay during both the experiment and sample assay. From
this adjusted figure, the relative distribution of blood was
deduced.
The time course of the effects of HDZ on relative tissue/
organ perfusion was studied by injecting either non-tumour
bearing mice, or those bearing MAC 26 or MAC 15A tu-
mours with `mTc-HMPAO 5 min, 1, 2 or 4 h after adminis-
tration of 1Omgkg-' HDZ, and then proceeding as above.
For inter-experiment comparisons, results were expressed as
percentages of control values, which were obtained from
animals which had received only 9'Tc-HMPAO. Examina-
tion of the data obtained showed that the absolute values of
counts/g tissue varied between experiments. This was due to
expected alterations in the radioactivity of different batches
of 99'Tc-HMPAO. However, the lungs consistently had the
highest counts/g tissue. Therefore, for intra-experimental
comparisons, the lungs were arbitrarily selected as a reference
tissue against which to compare the other tissues. All results
were compared to a control experiment, where non-tumour
bearing animals were injected with saline (1 ml per 100 g
bodyweight), and then 99'Tc-HMPAO according to the time
schedule described above.
The relationship between HDZ dose and perfusion was
investigated for both tumours. 99ITc-HMPAO was admin-
istered 5 min after HDZ (2.5 or 10 mg kg-'), and the assess-
ment of perfusion made as above.
Measurement of tumour chemosensitivity
Clonogenic assays
This method was used to investigate the influence of HDZ on
the efficacy of TCNU (1-20 mgkg-') and melphalan (1-10
mgkg-') against MAC 15A tumours. HDZ was administered
10 min after the TCNU, which is the time of peak tumour
concentration in NMRI mice (Double et al., 1988), and
15 min after the melphalan, which is the time of peak plasma
concentration in C3H mice (Lee & Workman, 1986). Tu-
mours were removed 24 h after dosing, and each tumour
assayed individually. Each tumour was made into a single
cell suspension by mincing with a scalpel and gently pressing
through a 625 holes cm-2 sterilised wire mesh. These cell
suspensions were washed in two changes of Hanks Balanced
Salt Solution (HBSS), centrifuged and the resulting cell
pellets resuspended in RPMI 1640 supplemented with foetal
calf serum (10%), sodium pyruvate (1 mM), penicillin/strep-
tomycin (50 IU ml-') and buffered by HEPES (25 mM); com-
plete media. From each tumour cell suspension, 104 viable
cells (as determined by trypan blue exclusion) were plated out
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chosen from preliminary experiments as giving an appropri-
ate, reproducible number of colonies. Colonies comprising 50
cells or more were counted 4-5 days later with the aid of a
10 x 10 mm eyepiece grid lattice on an inverted microscope
with a x 4 objective lens. Ten grid area counts were made in
each culture well, and from this, the mean counts/well cal-
culated by multiplying the mean counts/grid by (the area of
the well/the area of the grid). Cytotoxic effects for each
treatment were assessed by comparison of the plating effi-
ciencies obtained for dosed tumours with those for control
tumours assayed at the same time. In this study, the average
yield of viable cells from untreated MAC 15A tumours was
1.6 x 107 cells per g tumour tissue. This cell yield was not
affected by any of the treatments used. The plating efficiency
of control tumours was 10.8-25%.
In vivo assay
Due to differences in the morphology and growth charac-
teristics of MAC 26 and MAC 15A tumours, different pro-
tocols were necessary to assess their sensitivity to TCNU and
melphalan: the method for the assessment of the chemosen-
sitivity of the slow growing MAC 26 tumours has been des-
cribed (Bibby et al., 1988). Tumour volumes were assessed
over a period of 2-3 weeks by twice-weekly calliper measure-
ments of two perpendicular diameters. Volumes were cal-
culated from the equation: Volume = (a2b)/2, where a is the
smaller diameter and b the larger diameter of the tumour
(Geran et al., 1972). Volume measurements for each tumour
were normalised to their initial values, and a calculation
made of the time taken for the tumours to reach a relative
tumour volume of 2 (RTV2). The chemosensitivity of the
rapidly growing MAC 15A tumours was assessed in terms of
both tumour weight inhibition at 7 days after treatment
(Bibby et al., 1989b) and time to reach RTV2.
Bone marrow toxicity
In vivo colonyforming units-spleen (CFU-S) assay
An adaptation of the method of Till & McCulloch (1961)
was used to assess in vivo the influence of HDZ on the acute
bone marrow toxicity of TCNU (2.5-30mg kg-') or mel-
phalan (2.5 or 5 mg kg-') in mice bearing MAC 15A tu-
mours (two per group). HDZ (10 mg kg-') was administered
Omin after the TCNU or 15 min after the melphalan, and
bone marrow toxicity assessed 24 h after the last dose. Each
experiment involved investigating one drug concentration
with or without HDZ.
Removal ofbone marrow
Bone marrow was aspirated from both femora of each pair
of mice by flushing with 1-2 ml HBSS. These individual
suspensions were pooled to give one per group. An addi-
tional control suspension was obtained from two untreated
mice for each drug level tested. These marrow suspensions
were made up to 10 ml and stored on ice until injection,
which was always within 1 h of removal from the animal.
The number of cells in each suspension was counted using a
Neubauer haemocytometer and dilutions made to give app-
roximately 106 cells ml -'. These diluted cell suspensions were
then injected (0.2 ml mouse-' i.v.) into groups of 5-6 mice
which had previously been anaesthetised (Saffan 36 mg kg-'
or ether) and exposed to supralethal X-irradiation (11.7 Gy mouse-'). Seven days later these mice were killed, their
spleens removed, fixed in Bouin's fluid and the number of
surface colonies counted. The surviving fraction was cal-
culated as the number of colonies observed in the treated
groups compared with those in the control.
Statistical analysis
Differences between control and treated groups were
quantified by use of a two tailed un-paired students t-test.
For the clonogenic assay results, the per cent survival/drug
dose curves were fitted by least squares linear regression on
the log transformed data. Ninety five per cent confidence
limits were calculated for the slopes of all curves (Clarke,
1980).
Results
Tumour vasculature andbloodflow
Control tumours Comparison of Figures la and lb shows
that, in this well differentiated MAC 26 tumour, the func-
tional blood vessels are associated with the tumour stroma,
with this stroma supporting a thin layer of viable tumour
cells. The results presented here show that MAC 26 tumours
also have a high per cent functional vasculature, which is
consistent with the fact that these tumours can grow very
large (greater than 10 x initial volume) without becoming
necrotic. MAC 15A tumours, by contrast, are poorly
differentiated (Figure Ic) and poorly vascularised (Figure ld). Figure lc shows the formation of 'cords' of viable tumour
cells, with necrosis at distances greater than -1501tm from
the central, functional blood vessel.
The results obtained by the use of 99mTc-HMPAO showed
that the perfusion of the normal tissues studied was con-
sistently in the rank order: lungs > kidneys > liver, with the
tumour tissues being considerably less well perfused than the
liver tissue, (Figure 2). There was no difference between the
non-tumour animals, and those bearing MAC 26 or 15A
tumours in terms of the perfusion of the normal tissues
studied.
Influence ofHDZ on tumour vasculature andbloodflow
In this study, all doses of HDZ were well tolerated, with no
morbidity or mortality observed.
HDZ caused both a decrease in tumour perfusion and a
shutdown of tumour vasculature. Previous work in this
laboratory (N. Patel, unpublished data) using H33342 has
shown that this vascular shutdown was maximal by 5 min.
We have shown here (Figure 3) that the magnitude of the
vascular shutdown was related to both dose and tumour
differentiation state: 10 mgkg-' caused a 80% shutdown of
MAC 26 vasculature, from 5.4% to 1.1% (P<0.001), but a
50% shutdown of MAC 15A vasculature, from 1.9% to
0.95% (P<0.1). No shutdown was seen with 2.5mgkg-' HDZ, or with 30mgkg-' TCNU. The influence of 5mg kg-' HDZ on the vasculature of MAC 26 tumour was
intermediate between that of 2.5mgkg-' and that of 10mg kg-' (Figure 3).
The use of 99mTc-HMPAO showed that the HDZ-induced
decrease in tumour perfusion was also related to both dose
and differentiation state: 10mgkg-' caused a 63% decrease
for MAC26 (P<0.1), but only a 20% decrease for MAC
15A (NS). Perfusion of both tumours was returning to ap- proximately control levels by 4h after dosing (Figure 4). Again, 2.5mgkg-' was ineffective. Saline did not affect the
perfusion of any of the tissues studied (data not shown). As a dose of 1Omgkg-' was found to have the greatest influence on vasculature/perfusion, this was the dose used to
investigate the influence of HDZ on the efficacy ofmelphalan
or TCNU.
Chemosensitivity
HDZ (10 mgkg-') enhanced the activity of melphalan (1-10
mgkg-') against MAC 15A tumours (enhancement ratio =
2.1), but the effect on the activity of TCNU (1-20 mgkg-')
was less marked (enhancement ratio = 1.7). These enhance-
ment ratios were calculated as the ratio of the slopes of the regression lines shown in Figures 5a and Sb. The gradients of these lines (to 95% confidence limits) were: melphalan alone
= - 0.315 ± 0.062, melphalan with HDZ = - 0.674 ± 0.057; TCNU alone = -0.111 0.021, TCNU with HDZ = -0.189a
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Figure I a, Histology of a MAC 26 tumour, stained with H & E. (Bar = 200 1tm). b, Vasculature of a MAC 26 tumour, stained
with H33342. c, Histology of a MAC 15A tumour, stained with H & E. (Bar = 150 pm). d, Vasculature of a MAC 15A tumour,
stained with H33342.
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Figure 2 Relationship between perfusion of MAC 26 and 15A
tumours and that of other tissues. Each point = mean + 1 s.d. of
5 independent observations. _= Non tumour bearing,
1 = MAC 26, E1 = MAC 15A.
+0.043. It was found that 20mg kg-' TCNU gave a per
cent survival of 0 when administered without HDZ. There-
fore the data presented in Figure 5b is for 1-O mg kg-'.
In vivo assay
The addition of HDZ (10 mg kg-') increased the time taken
for MAC 26 tumours administered with melphalan (10 mg
kg-') to reach a relative tumour volume of 2 (RTV2) from
8.7 ± 2.1 to 15.5 ± 1.1 days, an increase by a factor of 1.8.
HDZ (10 mg kg-') also caused a dose related enhancement
of the efficacy of melphalan against MAC 15A tumours,
whether the results are expressed in terms of tumour weight
inhibition, or of the time taken for tumours to reach RTV2
(Table I). Melphalan alone caused a 43 ± 13% reduction in
tumour weight, and delayed the time to RTV2 from 2.8 ± 0.5
to 4.1 ± 0.6 days. The addition of HDZ (1Omg kg-') in-
creased the tumour weight inhibition, by a factor of 1.6, to
70 ± 16% (P<0.01), and delayed the time to RTV2, by a
factor of 2.5, from 4.1 ± 0.6 to 10.3 ± 5.3 (P<0.01). HDZ
(2.5 mg kg-') was ineffective.
HDZ (10 mg kg-') did not significantly alter the efficacy of
TCNU (30 mg kg-') against either MAC 26 tumours (data
not shown), or MAC 15A tumours (Table I). TCNU alone
increased the time for MAC 15A tumours to reach RTV2
from 2.5 ± 1.0 days to 6.3 ± 2.1 days. After the addition of
HDZ, the time to RTV2 was 6.1 ± 1.9 days.
Bone marrow toxicity assay
HDZ (10 mg kg-') did not alter the acute toxicity of TCNU
(2.5-15 mg kg-') against murine bone marrow stem cells
(data not shown), but did increase that of melphalan (5 mg
kg-') on both occasions that this experiment was carried out
(Table II) (P<0.001).
Discussion
We have used a combination of two complimentary techni-
ques; H33342 and 99mTc-HMPAO, to investigate the vas-
culature and perfusion of two members of the panel of MAC
tumours. The use of H33342 provides information which
cannot be deduced by the use of radioactive isotopes such as
99mTc-HMPAO. It allows direct visualisation of the tumour
vasculature which is functional at a given moment, and
showed both that the well differentiated MAC 26 tumours
were well vascularised, with blood vessels running through
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Figure 3 Influence of HDZ (10 or 2.5 mg kg-') on the functional vasculature of MAC 26 or MAC 15A tumours, and the influence of TCNU (30 mg kg-') on the functional vasculature of MAC 26 tumours, as measured by the use of H33342. Each bar =- mean + 1 s.d. of five independent observations. _ = Control, = = HDZ (10mgkg-'), 1I = HDZ (5mgkg-'), =I = HDZ (2.5 mg kg-'), 1 = TCNU (30 mgkg-').
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Figure 4 Time course ofthe effects ofHDZ (10mg kg-') on the relative perfusion ofMAC 26 and MAC lSA tumours over 240 min as measured by the use of99mTc-HMPAO. Each point = mean + I s.d. offive independent observations. * = MAC 26, * = MAC ISA.
the tumour stroma, and the poorly differentiated MAC 15A
tumours were poorly vascularised with a 'corded' structure
similar to that shown in many papers, from Thomlinson &
Gray (1955) to Hirst et al. (1991). We have shown previously
that the vascularisation offive members of the panel of MAC
tumours was directly related to their differentiation state
(Quinn et al., 1991), with well differentiated tumours being
significantly better vascularised than those which were poorly
differentiated. The two tumours described here represent the
two ends of this spectrum.
The results obtained by the use of 99mTc-HMPAO showed
that both MAC 26 and MAC 15A tumours were poorly per-
fused with blood, relative to several normal tissues. These are
in agreement with the results of Hammersley et al. (1987)
who used 99'Tc-HMPAO to investigate relative tissue per-
fusion in Balb c mice bearing either PM 2 sarcoma or PC 6
plasmacytoma. Both the H33342 and the 99mTc-HMPAO
techniques showed that the vasoactive agent HDZ caused a
decrease in functional tumour blood perfusion, the mag-
nitude of which was related to both HDZ dose and tumour
differentiation state. The time of onset of the shutdown
effect, as shown in our previous experiments using H33342,
was similar to that shown by Okunieff et al. (1989). The
degree of vascular shutdown of both of the tumours in this
study was greater than that shown by Trotter et al. (1989),
who demonstrated that 10 mgkg-' HDZ caused the aboli-
tion of perfusion in 36% of the vessels within SCCVII
tumours. This may reflect the differentiation state of this
tumour. There was good agreement between the H33342 and
the 99Tc-HMPAO methods as to the magnitude of the influ-
ence of 10mgkg-' HDZ.
In vivo tumour weight inhibition measurement and in vivo
to in vitro clonogenic assays, have demonstrated a com-
parable degree of enhancement of HDZ of the efficacy of
melphalan against MAC 15A tumours. This enhancement is
similar in magnitude to that demonstrated elsewhere (Strat-
ford et al., 1988; Chaplin et al., 1989). However, Stratford et
al. (1988) deduced that the addition of HDZ did not increase
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Figure 5 a, Influence of HDZ (10 mg kg-') on the potency of
melphalan (1-1O mg kg-') against MAC 15A sc tumours. Each
point = mean + I s.d. of 5-6 independent observations. i
= Melphalan, * = with HDZ. b, Influence of HDZ (10 mg kg-')
on the potency of TCNU ( -Omg kg-') against MAC 15A sc
tumours. Each point = mean + 1 s.d. of 5-12 independent
observations. 0 = TCNU, * = with HDZ.
the bone marrow toxicity of melphalan (measured in terms of
melphalan LD50 at 90 days). We have demonstrated in this
study that HDZ caused a significant increase in the acute
bone marrow toxicity of melphalan at a dose whose efficacy
we have shown to be increased by HDZ. Therefore, the
increase in activity does not correlate with therapeutic advan-
tage. The enhancement by HDZ of the efficacy of TCNU
against MAC 15A tumours, as shown by in vivo to in vitro
clonogenic assays, was less marked than the increase shown
of melphalan effectiveness, but the acute bone marrow tox-
icity of TCNU was not increased.
Both Stratford et al. (1988) and Chaplin et al. (1989)
demonstrated by the use of clonogenic assays that HDZ
could markedly enhance the efficacy of melphalan when the
HDZ was administered as early as 2 h before dosing. This
result, taken in conjunction with the results presented here,
suggests that the potentiation caused by HDZ is due, at least
in part, to its influence on drug pharmacokinetics. This seems
logical in view of the fact that other chemopotentiators (e.g.
misonidazole), known to cause marked selective tumour vas-
cular shutdown (Murray et al. 1987) have also been shown to
alter drug pharmacokinetics (Randhawa et al., 1985), and it
is to this latter ability that the chemopotentiation has been
attributed (Randhawa et al., 1985). The potentiation of
CCNU by misonidazole has also been explained on the basis
of altered pharmacokinetics (Siemann, 1990). However, addi-
tional factors may be the existing tumour hypoxic fraction
and the fact that tumour vascular shutdown would alter both
intratumoural pH and hypoxia. The importance of these
factors would vary with the activity/potentiation of different
drugs, depending on their physicochemical properties.
Hydralazine (5 or 10 mg kg-') has been shown to cause
the mean arterial blood pressure (MABP) of mice to decrease
by 41-46% (Bibby et al., 1989a). This is similar to the values
presented elsewhere (Horsman 1989; Okunieff et al., 1989).
However, the lack of lethality observed in this study and
others (Stratford et al., 1988; Okunieff et al., 1989) confirms
that the decreased arterial blood pressure is adequately com-
pensated for by the selectively increased rate of perfusion of
critical normal tissues. Even so, a >40% decrease in MABP
is obviously clinically unacceptable. Decreased MABP is
likely to be the explanation for the observation that in
NMRI mice, HDZ (10 mg kg-') causes decreases in glom-
erular filtration rate (GFR), as measured by insulin clear-
ance, resulting in decreased TCNU clearance from plasma
and tissues (Bibby et al., 1992). Honess & Bleehen (1991)
demonstrated similar alterations in GFR by 5 mg kg-' HDZ
in C3H mice. This systemic influence of HDZ not only
results in increased drug AUC, but will also have a
significant effect on drug metabolism. The degree of potentia-
tion is likely to vary depending on the role of metabolism in
the activity of a particular agent, and with the site where
metabolism occurs. Nevertheless, on the basis of these obser-
vations, in this study the greatest potentiation of antitumour
activity should have been seen in those tumours where there
was the greatest vascular shutdown. The data for TCNU are
contrary to this. It is well known that the sensitivity of cells
Table I Influence ofHDZ (10mg kg-') on the efficacy ofmelphalan (10mg kg-',15 minutes afterdosing)
or TCNU (30 mg kg-', 10 min after dosing) against MAC l5A tumours in vivo
% tumour weight Time to reach RTV2
Treatment inhibition ( I s.d.) (days) (± I s.d.)
Control 2.8 _ 0.5
Melphalan alone 43 ± 13 4.1 ± 0.6
Melphalan plus 10mg kg-' HDZ 70±16a 10.3 5.3a
Melphalan plus 2.5 mg kg-' HDZ 38 ± 4 3.9 _ 0.3
Control 2.5 1.0
TCNU alone 63 ± 19 6.3 ± 2.1
TCNU plus 10mg kg-' HDZ 67 ± 2.4 6.1 + 1.9
Note: ap<0.01.
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Table II Influence ofHDZ(10mg kg-') on theacutebonemarrow toxicity ofmelphalan (2.5-5 mg kg-',
15 min after dosing) in NMRI mice bearing MAC 15A tumours
Per cent
Treatment Survival (±1 s.d.)
Melphalan 2.5 mg kg' 0.51 ± 0.16
Melphalan 2.5 mg kg-' plus 10mg kg- I HDZ 0.49 ± 0.22
Melphalan 5 mg kg-' 0.16 ± 0.12
Melphalan 5 mg kg'- plus 10 mg kg-' HDZ 0.01 ± 0.02a
Note: ap<0.001.
to nitrosoureas is dependent upon their intracellular concen-
tration of the DNA repair enzyme 06-alkylguanine DNA
alkyltransferase (AT) (reviewed in D'Incalci et al., 1988).
Previous studies in this laboratory have demonstrated MAC
26 tumours to have high levels of AT (Lunn et al., 1989). So,
even though MAC 26 tumours are less resistant to TCNU
than to other nitrosoureas, a fact which is thought to be due
to the increased water solubility of TCNU, it will not be
possible to increase the activity of TCNU by the use of
HDZ, unless the increase is sufficient to saturate the ability
of AT to prevent the formation of DNA-interstrand cross-
links. We have some evidence in support of this theory in the
form of results obtained from preliminary investigations of
the ability of HDZ to increase the activity of TCNU against
MAC 13 tumours, which Lunn et al. (1989) demonstrated to
have particularly low levels of AT. We found that there was
a significant (P<0.05%) increase in TCNU antitumour
activity when measured in terms of tumour weight inhibition
at 14 days.
There are several important factors that must be borne in
mind when considering the clinical relevance of the results
described in this paper. The first is that, in common with
most other investigations of the perfusion/vasculature of ex-
perimental tumours, all of the tumours used here were grown
subcutaneously. While the MAC system of tumours has been
shown to be a good model for clinical large bowel cancer in
terms of other relevant parameters, it remains to be estab-
lished if the vascular supply of tumours grown in this
superficial site is as representative. Field et al. (1991) showed
that HDZ (5 mg kg-' i.p.) caused a decrease in the blood
flow through a group of transplanted malignant fibrous
histiocytomas, whereas the primary tumour from which they
were derived did not respond. Rowell et al. (1990) showed by
the use of SPECT and 99'Tc-HMPAO that single dose oral
HDZ (0.37-2.86 mg kg-') caused the blood flow through
clinical lung tumours to increase rather than decrease. These
results highlight the importance of selecting a clinically
relevant model for investigation of the influence of vasoactive
drugs on antitumour activity.
In conclusion, this study has investigated the vasculature
and perfusion of two members of the panel of MAC
tumours. We have shown that there are direct relationships
between differentiation state and degree of vascularisation
and between vascular patterns and tumour architecture in the
two tumours described here. We have also demonstrated that
the normal perfusion of these tumours was consistently
markedly less than that of lung, liver or kidneys. Intravenous
administration of HDZ caused a shutdown of tumour vas-
culature and a decrease in tumour perfusion, the magnitude
of both of which was related to dose and tumour
differentiation state. Use of in vivo to in vitro clonogenic
assays showed that HDZ potentiated the efficacy of mel-
phalan, and slightly enhanced the efficacy of TCNU when
given 10 or 15 min respectively after dosing. However, the
addition of HDZ increased the acute bone marrow toxicity
of melphalan, but did not alter that of TCNU. Thus the
enhancement of the efficacy of TCNU represents a true
therapeutic gain, whereas the increase of melphalan activity
does not. Further work is required to investigate the vas-
culature, perfusion and response to chemotherapy/
vasoactives of these tumours at more clinically relevant sites.
The authors are grateful for the support of the Yorkshire Cancer
Research Campaign (PKM Quinn), and Bradford's War on Cancer.
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